What is Tirzepatide?
Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual agonist at both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism makes it a subject of significant research interest in metabolic science.
Research Dosing Parameters
- Typical starting dose: 2.5 mg (2500 mcg) per week
- Common vial size: 10 mg
- Reconstitution: 2–5 mL bacteriostatic water
- Note: Tirzepatide doses are often expressed in mg; use the mg unit toggle in the calculator
How to Reconstitute Tirzepatide
- Use sterile bacteriostatic water for reconstitution
- Inject water slowly along the vial wall — avoid direct contact with the powder
- Gently swirl; do not vortex or shake vigorously
- Inspect for clarity before use — should be clear and colorless
- Store at 2–8°C; use within 28 days of reconstitution
FAQ
How do I switch to mg units in the calculator? In the dose section of the calculator above, toggle from “mcg” to “mg” to enter milligram doses directly.
What is a typical starting research dose for tirzepatide? Research protocols commonly begin at 2.5 mg per week, with titration every 4 weeks as tolerated.
How does tirzepatide differ from semaglutide? Tirzepatide targets both GLP-1 and GIP receptors (dual agonist), while semaglutide targets only GLP-1. Research suggests the dual action may produce different metabolic effects.